Prognostic value of AR mutation in primary African American prostate cancer
Prognostic value of AR mutation in primary African American prostate cancer
批准号:
8416144
负责人:
SHAHRIAR KOOCHEKPOUR
金额:
$15.37万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2013-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Prostate cancer (PCa) incidence and mortality rate is higher in African-American (AA) men than in Caucasian Americans (CAs). AA men with PCa also present with higher tumor volume, more advanced tumor stage, and higher Gleason grade. Prostate carcinogenesis and tumor progression are related highly to the expression and activity of the androgen receptor (AR). Mutations, genomic amplification, and polymorphisms in the CAG/GGC repeat also can increase AR expression and/or activity. In CAs, AR mutations are infrequent (<1%) in localized tumors, but occur at a higher frequency in advanced, metastatic, or hormone-refractory disease. In AAs, the prevalence of AR mutations and their prognostic significances in primary PCa are unknown. We discovered genomic amplification and somatic mutation of AR in a PCa cell line established by our laboratory from an AA patient with localized PCa. In addition, in a set of 41 radical prostatectomy samples (25 AAs and 16 CAs), we identified 4 AR mutations, 3 somatic and 1 germline in AA patients. These data led us to hypothesize that AR mutations in primary African-American PCa may be more frequent than expected and may contribute to disease aggressiveness or serve as a prognostic factor. We propose the following Specific Aims: Aim 1: Determine the prevalence of AR mutations in primary African-Americans PCa. Exon-specific primers of the AR gene will be used to sequence genomic-DNA extracted from laser-captured cells of paraffin- embedded tissue sections of radical prostatectomy specimens to determine the prevalence of somatic AR mutations in 250 AA patients with primary untreated PCa. Aim 2: Determine the contribution of AR mutation to PCa heterogeneity in African-Americans. Clinical and histopathological heterogeneity of PCa present a major challenge to therapeutic interventions. Differences in AR expression and microvascular density are considered as the two major contributors to PCa heterogeneity. We will use flow cytometry and immunohistochemical staining to examine AR and microvessel density in AA PCa with mutated AR. Aim 3: Define the prognostic significance of AR mutations in primary African-American PCa. We will determine the prognostic significance of AR mutations alone or in combination with AR and PSA polymorphic sites in relation to prognostic clinical or histopathological variables including family history, age, PSA, 5 year PSA-free survival, primary Gleason pattern, Gleason sum, and TNM stage. Significance: The results of this exploratory (R21) project will provide both the prevalence and prognostic value of AR mutations and may help us to understand better and address more effectively the racial disparity of the aggressiveness of PCa in AAs when compared to Caucasians.
PUBLIC HEALTH RELEVANCE: The incidences, mortality, and aggressiveness of prostate cancer (PCa) in African-American (AA) men are higher than in Caucasians. To understand and address the racial disparity of the disease aggressiveness, reliable prognostic factors are needed. Our discovery of a high frequency of androgen receptor mutations in untreated localized AA PCa might have prognostic significance that would provide us a more effective therapeutic approach.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/ijc.28919
发表时间:
2014-12-01
期刊:
International journal of cancer
影响因子:
6.4
作者:
[Parray A, Siddique HR, Kuriger JK, Mishra SK, Rhim JS, Nelson HH, Aburatani H, Konety BR, Koochekpour S, Saleem M]
通讯作者:
Saleem M
Therapeutic Efficacy of Riluzole in Prostate Cancer
-
批准号:8751365
-
项目类别:
-
资助金额:$18.47万
-
财政年份:2014
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Metabotropic Glutamate Receptor 1 in African American Prostate Cancer
-
批准号:8675361
-
项目类别:
-
资助金额:$22.16万
-
财政年份:2014
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Therapeutic Efficacy of Riluzole in Prostate Cancer
-
批准号:8889227
-
项目类别:
-
资助金额:$22.16万
-
财政年份:2014
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Metabotropic Glutamate Receptor 1 in African American Prostate Cancer
-
批准号:8829801
-
项目类别:
-
资助金额:$18.47万
-
财政年份:2014
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
PROSAPOSIN, A NOVEL INFLAMMATORY RESPONSE FACTOR FOR PROSTATE CANCER PROGRESSION
-
批准号:8360448
-
项目类别:
-
资助金额:$20.04万
-
财政年份:2011
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans
-
批准号:8147010
-
项目类别:
-
资助金额:$18.27万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Prognostic value of AR mutation in primary African American prostate cancer
-
批准号:7989304
-
项目类别:
-
资助金额:$19.98万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans
-
批准号:8501024
-
项目类别:
-
资助金额:$39.17万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Significance of an novel germline AR mutation in black men with prostate cancer
-
批准号:8367933
-
项目类别:
-
资助金额:$11.52万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans
-
批准号:8288659
-
项目类别:
-
资助金额:$41.41万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans
-
批准号:8391445
-
项目类别:
-
资助金额:$16.87万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans
-
批准号:8035191
-
项目类别:
-
资助金额:$35.5万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Significance of an novel germline AR mutation in black men with prostate cancer
-
批准号:8037128
-
项目类别:
-
资助金额:$3.46万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
PROSAPOSIN, A PROMOTER OF PROSTATE CARCINOGENESIS
-
批准号:8168422
-
项目类别:
-
资助金额:$17.28万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Significance of an novel germline AR mutation in black men with prostate cancer
-
批准号:7877675
-
项目类别:
-
资助金额:$18.53万
-
财政年份:2010
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
PROSAPOSIN, A PROMOTER OF PROSTATE CARCINOGENESIS
-
批准号:7959912
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2009
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
PROSAPOSIN, A PROMOTER OF PROSTATE CARCINOGENESIS
-
批准号:7720482
-
项目类别:
-
资助金额:$13.95万
-
财政年份:2008
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
LSUHSC COBRE: PROJ 1: PRESPOSIN, A PROMOTER OF PROSTATE CARCINOGENESIS
-
批准号:7610785
-
项目类别:
-
资助金额:$14.3万
-
财政年份:2007
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Prosaposin, a novel tumor marker for prostate cancer
-
批准号:7071507
-
项目类别:
-
资助金额:$13.51万
-
财政年份:2006
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
Prosaposin, a novel tumor marker for prostate cancer
-
批准号:7230060
-
项目类别:
-
资助金额:$13.1万
-
财政年份:2006
-
负责人:SHAHRIAR KOOCHEKPOUR
-
依托单位:
国内基金
海外基金
登录
查看更多内容
"胚胎/生殖细胞发育特性激活”促进“神经胶质瘤恶变”的机制及其临床价值研究
-
批准号:82372327
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:马展
-
依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
-
批准号:82372328
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:项盈
-
依托单位:
基于时间序列间分位相依性(quantile dependence)的风险值(Value-at-Risk)预测模型研究
-
批准号:71903144
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2019
-
负责人:张申
-
依托单位:
基于VaR的水资源短缺风险综合模型体系与应用
-
批准号:51279006
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:王红瑞
-
依托单位:
基于VFM视角的公共基础设施项目PPP模式选择模型及应用研究
-
批准号:71102091
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:王东波
-
依托单位:
支持价值觉察的服务供应链运作模型及分析方法
-
批准号:71171066
-
项目类别:面上项目
-
资助金额:42.0万元
-
批准年份:2011
-
负责人:何霆
-
依托单位:
多核系统下调控模式识别的MapReduce模型及算法研究
-
批准号:61173025
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:霍红卫
-
依托单位:
有约束多项分布转录因子结合位点识别
-
批准号:60705004
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2007
-
负责人:刘立芳
-
依托单位:
不可压流体力学方程中的一些问题
-
批准号:10771177
-
项目类别:面上项目
-
资助金额:17.0万元
-
批准年份:2007
-
负责人:肖跃龙
-
依托单位:
Circle Packing理论与正规族理论研究
-
批准号:10701084
-
项目类别:青年科学基金项目
-
资助金额:15.0万元
-
批准年份:2007
-
负责人:黄小军
-
依托单位: